Expand ACER Menu
ACER MENU

About ACER

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna(R), is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ACER is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 99.2 M 9.92442E+07 2,003 2003 0.0% 2.56642E-06 814 814
UWM ProShares Ultra Russell2000 219.8 M 2.19791E+08 2,003 2003 0.0% 4.41601E-06 2 K 2031
VTWG Vanguard Russell 2000 Growth ETF 342.7 M 3.427E+08 1,175 1175 0.0% 1.73528E-05 6 K 6152
ITOT iShares Core S&P Total U.S. Stock Market ETF 25.9 B 2.58526E+10 3,675 3675 0.0% 0 2 K 1593
IWC iShares Microcap ETF 887.3 M 8.8732E+08 1,390 1390 0.01% 0.0001 65 K 65409
IWM iShares Russell 2000 ETF 48.0 B 4.80197E+10 1,992 1992 0.0% 0 473 K 472858
IWO iShares Russell 2000 Growth ETF 10.2 B 1.02471E+10 1,167 1167 0.0% 0 199 K 198505
VTWO Vanguard Russell 2000 ETF 1.6 B 1.6E+09 2,002 2002 0.0% 1.03346E-05 17 K 16920